LILRB4 has been shown to drive immune evasion and relapse in AML by inhibiting T cell activity and promoting tissue infiltration via the ApoE–LILRB4–SHP2–NFκB (nuclear factor κB) pathway. This evidence concerns the gene LILRB4 and acute myeloid leukemia.